Hims & Hers Expands Into Lab Testing to Boost Preventive Care
Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion.
/ 913 items
#Healthcare↓
FDA Approves Kura's Ziftomenib (Komzifti) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible NPM1 Mutation
The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.
Outlook ONS-5010 BLA Accepted; FDA Target Date Dec 31, 2025
Outlook Therapeutics' potential new treatment, ONS-5010 (LYTENAVA), is under FDA review following a successful BLA resubmission. The decision is expected by December 31, 2025.
Day One Acquires Mersana for $285M to Gain Emi-Le Cancer Drug
Day One is acquiring Mersana Therapeutics for up to $285 million to gain Emi-Le, a promising new drug candidate for adenoid cystic carcinoma, a cancer with few treatment options.
Korro Bio Announces Major Restructuring and Program Shifts
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.
LivaNova Unveils 2030 Growth Plan and Expands into New Health Markets
LivaNova outlines a strong 2030 roadmap with targets for high revenue growth, expanded margins, and new innovations in Epilepsy, Cardiopulmonary, and Sleep Apnea treatments.